Heparin Market

Global Heparin Market Size (2023 to 2028)

The size of the global heparin market is estimated to grow at a CAGR of 4.33% from 2023 to 2028 and be worth USD 13.6 billion by 2028 from USD 11 billion in 2023.

Impact of the COVID-19 pandemic on the heparin market:

The outbreak of COVID-19 has had a positive impact on the heparin market. During the COVID-19 era, abnormal blood clots are common in COVID-19 patients. People who have Covid positive are affected mainly by respiratory illnesses. Heparin is one of the drugs that can reduce respiratory inflation. Patients receive prophylactic doses of low-molecular-weight heparin for those admitted to the hospital with COVID-19. Clot-promoting antigens may lead to deep vein thrombosis and pulmonary embolisms, creating heparin opportunity. As per American Heart Association (JAHA), in 2021, people were given anticoagulation therapy of low-molecular-weight heparin for better treatment associated with coagulopathy and endotheliomas that lead to a better prognosis in a patient. All these factors are anticipated to fuel the growth rate of the heparin market. Investigating LMWH's interaction with the SARS-CoV-2 Spike protein helps establish a potent therapeutic strategy to reduce pulmonary embolism and thrombosis consequences in SARS-CoV-2 patients. Because of this, LMWH is still being studied and developed in clinical settings to increase its efficacy while also being utilized to treat COVID-19 patients.

MARKET DRIVERS:

The growing geriatric population worldwide and the increasing number of heparin products in various applications are primarily accelerating the development of the global heparin market.

Pulmonary embolism and deep vein thrombosis are chronic diseases affecting the older population. The geriatric population is constantly increasing across the globe. The number of people above 65 increased from 40.3 million to more than 54 million between 2010 and 2019, as per the U.S. Census Bureau. According to estimates, its population will total 78.0 million by 2035 and 94.8 million by 2060. Chronic diseases including coronary artery disease, venous thromboembolism, atrial fibrillation, and flutter are increasingly being detected in those over 65. This will make cardiovascular diseases even more prevalent, increasing the demand for and need for anticoagulant medications like low molecular weight and unfractionated heparin. The increased use of heparin products has improved the creation of LMWH. Factors like technological development and the launch of new products are also anticipated to have a substantial impact on the growth of the global market.

Increasing incidence of coagulation disorders, increasing awareness levels through programs, rising health care expenditure and initiatives undertaken by the government, rising number of accidents and medical surgeries, and increasing patient awareness, research, and development are the factors expected to boost the growth rate of the heparin market. Furthermore, it is predicted that the advent of synthetic and semi-synthetic heparin mimics that help treat inflammatory, coagulation, and cancerous illnesses would present profitable opportunities for heparin adoption.

On the other hand, heavy dependency on heparin derived from porcine and governmental approval to produce drugs that takes a long time is majorly hindering the growth of the heparin market. In addition, an increase in competition and heparin's side effects are significant challenges for the heparin market. Some effects are spontaneous bleeding from several places in the body, including open wounds or surgical sites, and heparin-induced thrombocytopenia, in which heparin activates the body's immune system to develop antibodies against its platelets, causing the risk of bleeding due to a reduction in platelets.

REPORT COVERAGE:

This research report on the global heparin market has been segmented and sub-segmented based on product, application, end-user & region.

Heparin Market – By Product:

• Unfractionated Heparin
• Low Molecular Weight Heparin (LMWH)
• Ultra-low Molecular Weight Heparin

Based on the product, the low molecular weight heparin (LMWH) segment held a significant share of the global heparin market in 2022 due to its consistent anticoagulant effect when compared to other heparin types as unfractionated heparin; the demand for the product is mainly due to the increase in the usage of LMWH in the treatment of COVID-19 patients. According to a 2021 Springe report, heparin reduces the death of COVID-19 patients and lowers mortality by 72% in those with moderate or mild illnesses. Therefore, this is anticipated to increase patient use of the chemical.

Heparin Market - By Application:

• Venous Thromboembolism
• Coronary Artery Disease
• Atrial Fibrillation

Based on the application, the coronary artery disease segment accounted for the highest share of the heparin market in 2022 due to the increased heart-related problems across the globe. In addition, the rising prevalence of chronic diseases such as cardiovascular disorders, deep vein thrombosis, pulmonary embolism, and renal diseases is considered a significant factor driving the overall market. For instance, in 2019, according to the World Health Organization (WHO, an estimated 17.9 million people died from cardiovascular diseases (CVDs), representing 32% of all global deaths.

Heparin Market – By End-User:

• Out-patient
• In-patient

Based on the end-user, the outpatient segment led the heparin market in 2022. Outpatients have an advantage over other patients because of the decrease in hospital costs, including those associated with hospital admission and other forms of hospitality. A significant proportion of this market is primarily due to low prices, expanded service availability, and patient convenience.

Heparin Market – By Region:

• North America
• Europe
• Asia-Pacific
• Middle East Africa
• Latin America

Geographically, the European heparin market is predicted to have the most significant global market share during the forecast period. This is due to the rising elderly population, those prone to coronary artery diseases, the presence of market players, and a well-established distribution network. According to the Centers for Disease Control and Prevention (CDC), coronary artery disease (CAD) is one of the most common types of heart disease, causing more than 365,915 deaths in 2019 in Europe. As a result, growing cases of CAD will encourage the adoption of heparin across the region and in the coming years.

The North American heparin market is predicted to have a significant share next to Europe in the global market during the forecast period. This is due to increased cardiovascular diseases and accidents; the region's high proportion includes rising healthcare spending and patient awareness. In 2022, According to the CDC, heart disease is the primary reason for more deaths accounting for 659,000 annual deaths in the United States or 1 in every four fatalities. Each year, around 900,000 people are affected in the United States with venous thromboembolism, according to the CDC, which may result in the death of 10% to 30% of people within one month of diagnosis. U.S. and Canada are the dominating portions for heparin, making North American markets grow.

The Heparin market is anticipated to grow fastest in the Asia Pacific during the forecast period. Some of the factors influencing the market growth are the increasing elderly population, the large population with chronic diseases, an expanding economy, expanding healthcare infrastructure, the presence of untapped resources, economic development, and increasing initiatives by private & public organizations to the larger patient pool for cardiovascular diseases and an increase in the aging population. Additionally, the Asia Pacific is the region that supplies the most API and crude heparin. This benefits regional businesses like Pharmax Lifesciences. Generic medications whose patents have expired are produced locally at a reasonable price. On the other hand, high patient populations in nations with dense populations, like China and India, make them more susceptible to chronic illnesses.

TOP COMPANIES IN THIS MARKET:

The major players included in the heparin market are OPOCRIN S.P.A., Baxter., Aspen Holdings, B. Braun Medical Inc., Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd, Mylan N.V., Changzhou Qianhong Bio-pharma Co., ltd., Eisai Co., Ltd., Fresenius Kabi AG, Pfizer Inc., GlaxoSmithKline plc., LEO Pharma, Sanofi, Fresenius SE & Co. KGaA, Hikma Pharmaceuticals PLC, Nanjing Jianyou Biochemical Pharmaceutical Co., Novartis AG, SARIA SE & Co. KG, Shanghai Fosun Pharmaceutical Co., Ltd. and Hepalink.

RECENT HAPPENINGS IN THIS MARKET:

• In 2021, Fresenius Kabi announced two new presentations in the United States of Heparin Sodium in convenient, ready-to-administer Freeflex IV bags.
• In 2020, Opocrin SpA acquired Laboratory Derivati Organic SpA (LDO).